Page last updated: 2024-12-05

methyl acetoacetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Methyl acetoacetate, also known as ethyl 3-oxobutanoate, is a versatile synthetic building block in organic chemistry. It is a colorless liquid with a pleasant odor and is commonly used as a precursor for the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and fine chemicals. The compound is often prepared through the Claisen condensation reaction of ethyl acetate. Methyl acetoacetate exhibits tautomerism, existing in both keto and enol forms, which contributes to its reactivity. Its enol form is particularly reactive and readily undergoes electrophilic substitution reactions. The compound finds applications in the synthesis of various pharmaceuticals, such as vitamin K and the anti-inflammatory drug ibuprofen. It is also used in the production of agrochemicals, such as herbicides and insecticides. Due to its versatility as a synthetic building block and its involvement in various chemical reactions, methyl acetoacetate continues to be an active area of research in organic chemistry.'

methyl acetoacetate: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7757
CHEMBL ID3186053
CHEBI ID166454
SCHEMBL ID1162
MeSH IDM0046600

Synonyms (76)

Synonym
methyl acetylacetate
3-oxobutanoic acid methyl ester
methyl 3-oxobutyrate
acetoacetic acid methyl ester
acetoacetic methyl ester
ccris 2302
ai3-06000
methyl acetylacetonate
1-methoxybutane-1,3-dione
einecs 203-299-8
methylester kyseliny acetoctove [czech]
hsdb 1083
methylacetoacetate
methylacetoacetic acid
CHEBI:166454
105-45-3
inchi=1/c5h8o3/c1-4(6)3-5(7)8-2/h3h2,1-2h
methyl 3-oxobutanoate
butanoic acid, 3-oxo-, methyl ester
methyl acetoacetate
acetoacetic acid, methyl ester
methyl acetoacetate, reagentplus(r), 99%
methyl acetoacetate, produced by wacker chemie ag, burghausen, germany, >=99.0% (gc)
A0650
3-oxobutyric acid methyl ester
AKOS000118978
A801244
methyl 3-oxidanylidenebutanoate
NCGC00248545-01
3-oxo-butyric acid methyl ester
NCGC00257716-01
dtxcid706716
dtxsid9026716 ,
cas-105-45-3
tox21_200162
BBL011420
FT-0672079
STL146527
ec 203-299-8
cw4i82qax1 ,
unii-cw4i82qax1
methylester kyseliny acetoctove
FT-0621778
S3091
SCHEMBL1162
methyl acetoacetate [hsdb]
methyl acetoacetate [mi]
methylaceto acetate
mecoch2coome
methyl-3-oxobutanoate
methyl 3-oxo-butyrate
3-oxobutanoic acid, methyl ester
aceto-acetic acid methyl ester
methyl acetoactate
3-oxo-butanoic acid methyl ester
methyl aceto acetate
CHEMBL3186053 ,
J-001423
J-522584
methyl acetoacetate, lonza quality, >=99% (gc)
F0001-0105
mfcd00008784
methyl acetoacetate, analytical standard
bdbm50502126
methyl acetoacetate, >=99%
methyl acetoacetate, vetec(tm) reagent grade, 98%
acetoacetic acid-methyl ester
methyl 3-oxobutanoic acid
acetoacetate methyl ester
HY-Y1298
methyl acetoacetate(maa)
Q63395658
D70329
CS-0017265
EN300-19130
Z104472888
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oxo carboxylic acidAny compound that has an aldehydic or ketonic group as well as a carboxylic acid group in the same molecule.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Maltase-glucoamylase, intestinalHomo sapiens (human)IC50 (µMol)19.00000.04003.46529.0000AID1509468
Lysosomal alpha-glucosidaseHomo sapiens (human)IC50 (µMol)19.00000.06002.28897.8000AID1509468
Sucrase-isomaltase, intestinalHomo sapiens (human)IC50 (µMol)19.00000.04902.72947.8000AID1509468
Probable maltase-glucoamylase 2Homo sapiens (human)IC50 (µMol)19.00000.54004.02447.8000AID1509468
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (23)

Processvia Protein(s)Taxonomy
maltose catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
starch catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
dextrin catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
maltose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
regulation of the force of heart contractionLysosomal alpha-glucosidaseHomo sapiens (human)
diaphragm contractionLysosomal alpha-glucosidaseHomo sapiens (human)
heart morphogenesisLysosomal alpha-glucosidaseHomo sapiens (human)
glycogen catabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
sucrose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
glucose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
lysosome organizationLysosomal alpha-glucosidaseHomo sapiens (human)
locomotory behaviorLysosomal alpha-glucosidaseHomo sapiens (human)
tissue developmentLysosomal alpha-glucosidaseHomo sapiens (human)
aorta developmentLysosomal alpha-glucosidaseHomo sapiens (human)
vacuolar sequesteringLysosomal alpha-glucosidaseHomo sapiens (human)
muscle cell cellular homeostasisLysosomal alpha-glucosidaseHomo sapiens (human)
neuromuscular process controlling postureLysosomal alpha-glucosidaseHomo sapiens (human)
neuromuscular process controlling balanceLysosomal alpha-glucosidaseHomo sapiens (human)
cardiac muscle contractionLysosomal alpha-glucosidaseHomo sapiens (human)
glycophagyLysosomal alpha-glucosidaseHomo sapiens (human)
sucrose catabolic processSucrase-isomaltase, intestinalHomo sapiens (human)
polysaccharide digestionSucrase-isomaltase, intestinalHomo sapiens (human)
carbohydrate metabolic processProbable maltase-glucoamylase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
catalytic activityMaltase-glucoamylase, intestinalHomo sapiens (human)
glucan 1,4-alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
alpha-1,4-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
protein bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
amylase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
carbohydrate bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
maltose alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
alpha-1,4-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
carbohydrate bindingLysosomal alpha-glucosidaseHomo sapiens (human)
maltose alpha-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
alpha-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
oligo-1,6-glucosidase activitySucrase-isomaltase, intestinalHomo sapiens (human)
sucrose alpha-glucosidase activitySucrase-isomaltase, intestinalHomo sapiens (human)
protein bindingSucrase-isomaltase, intestinalHomo sapiens (human)
carbohydrate bindingSucrase-isomaltase, intestinalHomo sapiens (human)
alpha-1,4-glucosidase activitySucrase-isomaltase, intestinalHomo sapiens (human)
glucan 1,4-alpha-glucosidase activityProbable maltase-glucoamylase 2Homo sapiens (human)
carbohydrate bindingProbable maltase-glucoamylase 2Homo sapiens (human)
alpha-1,4-glucosidase activityProbable maltase-glucoamylase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
apical plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
extracellular exosomeMaltase-glucoamylase, intestinalHomo sapiens (human)
tertiary granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
ficolin-1-rich granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
lysosomeLysosomal alpha-glucosidaseHomo sapiens (human)
lysosomal membraneLysosomal alpha-glucosidaseHomo sapiens (human)
plasma membraneLysosomal alpha-glucosidaseHomo sapiens (human)
membraneLysosomal alpha-glucosidaseHomo sapiens (human)
azurophil granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
lysosomal lumenLysosomal alpha-glucosidaseHomo sapiens (human)
intracellular membrane-bounded organelleLysosomal alpha-glucosidaseHomo sapiens (human)
extracellular exosomeLysosomal alpha-glucosidaseHomo sapiens (human)
tertiary granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
ficolin-1-rich granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
autolysosome lumenLysosomal alpha-glucosidaseHomo sapiens (human)
Golgi apparatusSucrase-isomaltase, intestinalHomo sapiens (human)
plasma membraneSucrase-isomaltase, intestinalHomo sapiens (human)
brush borderSucrase-isomaltase, intestinalHomo sapiens (human)
apical plasma membraneSucrase-isomaltase, intestinalHomo sapiens (human)
extracellular exosomeSucrase-isomaltase, intestinalHomo sapiens (human)
membraneProbable maltase-glucoamylase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1509468Inhibition of alpha-glucosidase (unknown origin)2019European journal of medicinal chemistry, Aug-15, Volume: 176Synthetic heterocyclic candidates as promising α-glucosidase inhibitors: An overview.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (11.11)18.2507
2000's8 (29.63)29.6817
2010's16 (59.26)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index50.63 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index76.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (50.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (7.41%)6.00%
Case Studies1 (3.70%)4.05%
Observational0 (0.00%)0.25%
Other24 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]